Key Drivers
- Margin Expansion
- Cash Flow Rebound
- Negative Equity
AIAI Summary
INDV is now primarily a merger-execution trade: SUBLOCADE's strong growth and cash generation support upside, but investors should not treat the $8.13 special dividend as recurring value and should demand successful Supernus integration and manufacturing transition before underwriting sustained re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Cash Flow Rebound
- •Negative Equity
INDV delivered sharply improved quarterly profitability and cash flow, but negative equity, rising debt, and weak liquidity remain significant balance-sheet risks.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Rebound failed
INDV remains bearish over the last month; hold caution unless it clears $35.70–$36.90, while a break below $34.20 would signal further downside.
Rebounded to $35.69 before dropping to $34.88 the next session
Sentiment & News
Key News Insights:
- •Supernus merger
- •Special dividend
- •Deal scrutiny
Indivior's Supernus merger could diversify its CNS business and reduce Sublocade reliance, while a special dividend and new institutional investment support sentiment despite deal and fairness-review uncertainty.
The developments are cautiously positive for INDV, but merger closing and valuation risks remain key catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings